Imexpharm Corporation (HOSE:IMP)

Vietnam · Delayed Price · Currency is VND

35,100

+100 (0.29%)

At close: Nov 3, 2026

Market Cap	5.41T -29.9%
Revenue (ttm)	2.29T -6.5%
Net Income	320.66B +1.4%
EPS	2,082.08 +0.5%
Shares Out	154.01M
PE Ratio	16.86
Forward PE	15.19
Dividend	500.00 (1.43%)
Ex-Dividend Date	Jul 13, 2026

Volume	2,911
Open	35,100
Previous Close	35,000
Day's Range	34,950 - 35,500
52-Week Range	32,650 - 57,000
Beta	0.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Jan 19, 2027

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietna... [Read more]

Industry Pharmaceutical Preparations

Founded 1997

Employees 1,444

Stock Exchange Ho Chi Minh Stock Exchange

Ticker Symbol IMP

Full Company Profile

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 10.34%.

Financial Statements